临床试验/NCT00003796

NCT00003796已完成2 期

Phase II Study of MGI-114 in Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)1 个研究点分布在 1 个国家目标入组 32 人开始时间: 1999年5月最近更新: 2013年2月11日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: National Cancer Institute (NCI)
入组人数: 32
试验地点: 1

研究概览研究设计入排标准研究组 & 干预措施研究者研究点记录与标识符相似试验

研究概览

简要总结

Phase II trial to study the effectiveness of irofulven in treating patients who have metastatic breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

详细描述

OBJECTIVES:

I. Evaluate the response rate and time to treatment failure in patients with refractory metastatic adenocarcinoma of the breast treated with irofulven.

II. Assess the qualitative and quantitative toxic effects of this drug in these patients.

III. Determine the population pharmacokinetics and the pharmacokinetics-pharmacodynamic relationships of this drug in these patients.

OUTLINE: This is a multicenter study.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

Arm I

Experimental

Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.

干预措施: irofulven (Drug)

研究者

发起方

National Cancer Institute (NCI)

申办方类型

Nih

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

2 期

Tipifarnib in Treating Patients With Metastatic Malignant MelanomaRecurrent MelanomaStage IV Melanoma

NCT00060125National Cancer Institute (NCI)40

已完成

2 期

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsGastrinomaMetastatic Gastrointestinal Carcinoid TumorInsulinomaRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaSomatostatinomaWDHA SyndromePancreatic Polypeptide TumorGlucagonoma

NCT00075439National Cancer Institute (NCI)90

已完成

2 期

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerRecurrent Neuroendocrine Carcinoma of the SkinStage II Neuroendocrine Carcinoma of the SkinStage III Neuroendocrine Carcinoma of the Skin

NCT00068783National Cancer Institute (NCI)40

已完成

2 期

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)Metastatic Castration-Resistant Prostate Cancer Patients

NCT03643107Allarity Therapeutics15

已完成

2 期

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer

NCT00053365National Cancer Institute (NCI)61